Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
Saved in:
| Published in: | Research and Practice in Thrombosis and Haemostasis |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2022
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
- Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay
- The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis
- Preclinical Efficacy and Safety Evaluation of a Novel Controlled‐Expansion ePTFE‐Covered TIPS Stent in a Swine Model
- Age and body weight-adjusted infusion rate (mg/kg/h) as risk factors for vancomycin infusion reaction in patients receiving perioperative antimicrobial prophylaxis: a retrospective cohort study
- Factor eight inhibitor bypassing activity for refractory bleeding in coronary artery bypass grafting: A propensity‐matched analysis
- In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan